Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-22T03:10:13.007Z Has data issue: false hasContentIssue false
  • English
  • Français

Cognitive screening for early detection of mild cognitive impairment

Published online by Cambridge University Press:  07 October 2020

Ann T. Nguyen  and
Grace J. Lee
Ann T. Nguyen
Affiliation:
Department of Psychology, School of Behavioral Health, Loma Linda University, Loma Linda, CA, USA
Grace J. Lee*
Affiliation:
Department of Psychology, School of Behavioral Health, Loma Linda University, Loma Linda, CA, USA
*
Email: [email protected]
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
International Psychogeriatrics , Volume 32 , Issue 9: Issue Theme: Enhanced Assessment Instruments for Older Adults with Major Neurocognitive Disorders , September 2020 , pp. 1015 - 1017
Copyright
© International Psychogeriatric Association 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alzheimer’s Association. (2018). 2018 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 14, 367–429.CrossRefGoogle Scholar
Brookmeyer, R., Gray, S. and Kawas, C. (1998). Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health, 88, 1337–1342.CrossRefGoogle ScholarPubMed
Buschke, H.et al. (1999). Screening for dementia with the memory impairment screen. Neurology, 52, 231.CrossRefGoogle ScholarPubMed
Evin, G. (2016). Future therapeutics in Alzheimer’s disease: development status of BACE inhibitors. BioDrugs, 30, 173–194.CrossRefGoogle ScholarPubMed
Judge, D., Roberts, J., Khandker, R., Ambegaonkar, B. and Black, C. M. (2019). Physician perceptions about the barriers to prompt diagnosis of mild cognitive impairment and Alzheimer’s disease. International Journal of Alzheimer’s Disease, 2019, 1–6.Google ScholarPubMed
Lehrner, J.et al. (2005). Annual conversion to Alzheimer disease among patients with memory complaints attending an outpatient memory clinic: the influence of amnestic mild cognitive impairment and the predictive value of neuropsychological testing. Wiener Klinische Wochenschrift, 117, 629–635.CrossRefGoogle ScholarPubMed
Liyanage, S. I., Santos, C. and Weaver, D. F. (2018). The hidden variables problem in Alzheimer’s disease clinical trial design. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 4, 628–635.Google ScholarPubMed
Lopez, C. L.et al. (2017). The Alzheimer’s prevention initiative generation program: evaluating CNP520 efficacy in the prevention of Alzheimer’s disease. The Journal of Prevention of Alzheimer's Disease, 4, 242–246.Google Scholar
McDonnell, M.et al. (2019). Verbal fluency as a screening tool for mild cognitive impairment. International Psychogeriatrics, 32, 1055–1062.Google Scholar
McMaster, M., Kim, S., Clare, L., Torres, S. J., D’Este, C. and Anstey, K. J. (2018). Body, Brain, Life for Cognitive Decline (BBL-CD): protocol for a multidomain dementia risk reduction randomized controlled trial for subjective cognitive decline and mild cognitive impairment. Clinical Interventions in Aging, 13, 2397–2406.CrossRefGoogle ScholarPubMed
Mehta, D., Jackson, R., Paul, G., Shi, J. and Sabbagh, M. (2017). Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opinion on Investigational Drugs, 26, 735–739.CrossRefGoogle Scholar
Nasreddine, Z. S. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53, 695–699.CrossRefGoogle ScholarPubMed
Oltra-Cucarella, J.et al. (2018). Differential effects of cognition-focused interventions for people with Alzheimer’s disease: a meta-analysis. Neuropsychology, 32, 664.CrossRefGoogle ScholarPubMed
Pinto, T. C.et al. (2018). Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer’s Disease (AD) in the elderly? International Psychogeriatrics, 31, 491–504.CrossRefGoogle ScholarPubMed
Rodakowski, J., Saghafi, E., Butters, M. A. and Skidmore, E. R. (2015). Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: an updated scoping review. Molecular Aspects of Medicine, 43, 38–53.CrossRefGoogle ScholarPubMed
Singer, M., Romero, B., Koenig, E., Förstl, H. and Brunner, H. (2005). Nightmares in patients with Alzheimer’s disease caused by donepezil. Therapeutic effect depends on the time of intake. Der Nervenarzt, 76, 1127–1128.CrossRefGoogle Scholar
Tariq, S. H., Tumosa, N., Chibnall, J. T., Perry III, M. H. and Morley, J. E. (2006). Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder—a pilot study. The American Journal of Geriatric Psychiatry, 14, 900–910.CrossRefGoogle ScholarPubMed
Xu, W.et al. (2015). Meta-analysis of modifiable risk factors for Alzheimer’s disease. Journal of Neurology, Neurosurgery & Psychiatry, 86, 1299–1306.Google ScholarPubMed
Yaffe, K., Hoang, T. D., Byers, A. L., Barnes, D. E. and Friedl, K. E. (2014). Lifestyle and health-related risk factors and risk of cognitive aging among older veterans. Alzheimer’s & Dementia, 10, S111–S121.CrossRefGoogle ScholarPubMed